Essential Partners’s Verrica Pharmaceuticals VRCA Stock Holding History

Essential Partners’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2	Closed	-$8	–	2797
2025 Q2	$8	Buy	+2	New	+$11	﹤0.01%	2260

Other funds holding VRCA

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return

Essential Partners's VRCA Position: Q3 2025 in Review

Essential Partners sold out of Verrica Pharmaceuticals (VRCA) in Q3 2025, closing a stake of 2 shares — an estimated $8 sold.

Essential Partners first reported a position in VRCA in Q2 2025 and held it in 1 quarter. The position peaked at $8 in Q2 2025. 34 funds tracked by Wall St. Rank hold VRCA as of Q3 2025.

Essential Partners reported no remaining Verrica Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Essential Partners sold 2 Verrica Pharmaceuticals shares in Q3 2025, an estimated $8.
Essential Partners first reported a position in Verrica Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Essential Partners's Verrica Pharmaceuticals position peaked at $8 in Q2 2025.
34 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.